Agios Sep 21, 2020 Agios's Tibsovo Trial Fails to Meet Overall Survival Endpoint in IDH1-Mutated Bile Duct Cancer Jun 12, 2020 Agios Sells Royalty Rights to AML Drug Idhifa for $255 Million Jun 9, 2020 Thermo Fisher Scientific, Agios Pharmaceuticals to Codevelop Glioma Companion Diagnostic Jun 5, 2020 Targeted Therapies Continue to Yield Encouraging Data in Studies of IDH-Mutated AML, Glioma Apr 13, 2020 Agios Pushing Ahead in IDH-Mutated Solid Tumors With Tibsovo, Vorasidenib Premium Oct 1, 2019 Trial Data Reveals Progression Delay in Cholangiocarcinoma with Targeted IDH1 Drug Breaking News European Commission Approves Libtayo in PD-L1-Positive Non-Small Cell Lung Cancer NICE Backs Merck's Keytruda for PD-L1-Expressing Cervical Cancer Genialis Closes $13M Series A Funding Round Breast Cancer Study Leads to New Susceptibility Gene, Potential Treatment Strategies Incyte's Pemazyre Approved in Japan for FGFR1-Positive Rare Blood Cancers Cardiff Oncology Begins Phase II Onvansertib Trial in KRAS-, NRAS-Mutant Colorectal Cancer
